Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.
He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Andrew McConaghie
The closure reflects the consolidation of neuroscience research in Cambridge, Mass, and Brexit is not to blame, says Lilly.
Bill Anderson says Roche has scrapped budgets and improved productivity and re-energized teams. But is it too good to be true?
A pioneer in the field, can GSK’s investment in real world studies pay off?
As once-star investment funds fail, another major investor argues this is opportunity for UK biotech to demonstrate staying power.